Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cingulate Inc (CING)
NASDAQ:CING
Cingulate Inc (CING) Stock Price & Analysis
92 Followers
CING Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.75 - $23.41
Previous Close$0.88
Volume8.65K
Average Volume (3M)312.00K
Market Cap
$3.50M
Enterprise Value$5.12M
Total Cash (Recent Filing)$1.99M
Total Debt (Recent Filing)$3.60M
Price to Earnings (P/E)>-0.1
Beta-0.77
Next Earnings
May 08, 2024EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-30.39
Shares Outstanding5,010,471
10 Day Avg. Volume91,195
30 Day Avg. Volume311,998
Standard Deviation0.33
R-Squared0.03
Alpha-0.07
Financial Highlights & Ratios
Price to Book (P/B)-45.78
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-0.36
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
Cingulate Inc News
PremiumCompany Announcements
Cingulate Inc Bolsters Board, Targets Nasdaq Compliance
Bulls Say, Bears Say
Bulls Say
Business ExpansionIveda Solutions, Inc. is expanding its market presence with a series of new business contracts and a growing demand for its innovative solutions in smart cities, enterprises, and government sectors.
Earnings And Corporate StrategyFlexShopper, Inc. reported earnings that met or exceeded consensus and introduced a new strategy that maintains a positive outlook for the company's future.
Revenue Growth And Product DevelopmentIceCure Medical Ltd's revenue surpassed expectations and the company reported positive clinical results, coupled with a substantial regulatory milestone for its XSense product.
Bears Say
Clinical TrialsCingulate has paused clinical trials for its ADHD treatment, which may signal underlying financial issues.
EarningsCingulate reported a significant net loss in its latest financial results.
Financial HealthCingulate's path to filing a New Drug Application appears uncertain, indicating potential delays and financial stress.
---
Ownership Overview
66.85% Insiders
0.24% Mutual Funds
0.19% Other Institutional Investors
32.72% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
CING FAQ
What was Cingulate Inc’s price range in the past 12 months?
Cingulate Inc lowest stock price was $0.75 and its highest was $23.41 in the past 12 months.
What is Cingulate Inc’s market cap?
Currently, no data Available
When is Cingulate Inc’s upcoming earnings report date?
Cingulate Inc’s upcoming earnings report date is May 08, 2024 which is in 9 days.
How were Cingulate Inc’s earnings last quarter?
Cingulate Inc released its earnings results on Apr 01, 2024. The company reported -$4.925 earnings per share for the quarter, missing the consensus estimate of -$1.165 by -$3.76.
Is Cingulate Inc overvalued?
According to Wall Street analysts Cingulate Inc’s price is currently Overvalued.
Does Cingulate Inc pay dividends?
Cingulate Inc does not currently pay dividends.
What is Cingulate Inc’s EPS estimate?
Cingulate Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Cingulate Inc have?
Cingulate Inc has 3,977,171 shares outstanding.
What happened to Cingulate Inc’s price movement after its last earnings report?
Cingulate Inc reported an EPS of -$4.925 in its last earnings report, missing expectations of -$1.165. Following the earnings report the stock price went down -0.909%.
Which hedge fund is a major shareholder of Cingulate Inc?
Among the largest hedge funds holding Cingulate Inc’s share is GoalVest Advisory LLC. It holds Cingulate Inc’s shares valued at 24K.
---
Cingulate Inc Stock Smart Score
Not Ranked
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
― (―)
― (―)
Insider Transactions
Bought Shares
Worth $1.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.5%
Last 30 Days ▼ 11.7%
Last 30 Days ▼ 11.7%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-96.03%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-69.39%
Trailing 12-Months
Company Description
Cingulate Inc
Cingulate Inc is a clinical stage biopharmaceutical company utilizing its proprietary precision timed release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes.
---
CING Stock 12 Months Forecast
Average Price Target
―Technical Analysis
Best Analysts Covering CING
1 Year
1 Year Success Rate
0/4 ratings generated profit
1 Year Average Return
-81.03%
reiterated a buy rating 5 months ago
Copying Edward Woo's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -81.03% per trade.
---